novo nordisk ozempic - Search News

News

Novo Nordisk ousts CEO

MarketWatch on MSN · 1d

Novo Nordisk rode Ozempic’s success to becoming Europe’s top company. Now it’s faltering and its CEO is out.

Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight years in the role, the maker of Ozempic and Wegovy drugs announced on Friday.

Quartz on MSN · 1d

Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year

CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for the blockbuster drugs Ozempic and Wegovy, the company said Friday.

Fox Business on MSN · 1d

Novo Nordisk CEO steps down as Wegovy maker faces increased competition

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

16hon MSN

Ozempic Drugmaker’s CEO Pushed Out Amid Weight-Loss Market Challenges

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

21h

Ozempic-Maker CEO Ousted Over Pharma Company’s Rocky Market Downturn

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

1don MSN

Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its ...

1d

Novo Nordisk to Replace C.E.O. After Losing Edge in Weight-Loss Drugs

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

2d

Blocked From Selling Off-Brand Ozempic, Telehealth Startups Embrace a Less Effective Drug

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

2d

Ignore The Noise - Novo Nordisk Is A Clear Buy

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

Zacks Investment Research on MSN2d

Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk

Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results